オミックスベースの臨床試験市場規模、シェア、動向分析レポート：フェーズ別、試験デザイン別、適応症別、地域別、セグメント別予測、2025年～2030年

オミックスベースの臨床試験市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のオミックスベースの臨床試験市場規模は2030年までに517億7,000万米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 8.02％で拡大すると予測されています。オミックスは、分子研究における最先端のアプローチであることが判明しています。オミックスには、生物科学のすべてのセグメントが含まれます。プロテオミックス、ゲノミクス、トランスクリプトミクス、メタボロミクスなど、さまざまなセグメントがオミックスに分類されます。コロナウイルスの発生は、臨床試験における新しいアプローチ、モデル、技術の採用を加速させ、これは市場成長にプラスの影響を与えています。

COVID-19の発生は大混乱を引き起こし、産業のほとんどすべてのセクターを混乱させました。当初、COVID-19の発生は臨床試験のエコシステムに悪影響を及ぼし、多数の適応症について進行中の多くの試験に影響を与えました。しかし、2020年後半には、研究者がCOVID-19に対する革新的な治療やワクチンの開発に着手し、市場の回復と成長、CROの事業継続を支えました。がん領域の臨床試験が歴史的な高水準に達するなど、臨床試験活動が活発化しています。COVID-19感染を理解するための広範な調査により、オミックスベースの研究の応用に注目が集まっています。

例えば、2021年6月、テュービンゲン大学病院の研究者グループは、マルチオミックスアプローチを用いて、異なるCOVID-19ワクチン候補の遺伝子と免疫応答の比較分析に関する臨床試験を開始しました。バイオマーカーの同定を目的とした空間オミックスの応用が拡大していることが、市場の成長を押し上げる主要要因となっています。薬剤の有効性と毒性を研究するために、空間オミックスは主要な役割を果たし、創薬と開発を簡素化しています。バイオマーカーの同定は、臨床応用とともに、医薬品開発や創薬に広く利用されています。バイオマーカーは、疾患の経路や進行を特定し、原因を解明するために使用されます。

がんや心疾患などの慢性疾患の有病率の上昇や、新興国市場におけるオミックスベースの臨床試験に対する需要の高まりが、市場の成長を後押ししています。がんは米国における主要な死因の1つです。2018年だけでも、新規診断数は173万5,350人、がん関連死は60万9,640人と推定されています。シングルセルマルチOMIC分析は、がん治療開発の扉を開き、現在の治療選択肢をさらに前進させる新規ツールです。また、生物製剤の増加、先端技術への需要、個別化医薬品や希少疾病用医薬品へのニーズも市場を牽引しています。さらに、バイオテクノロジーと製薬産業の成長は、非侵襲的な機器、シングルセル・マルチオミックス技術の完全なアプリケーション、従来のラボの需要を促進しており、将来の市場成長を後押ししています。

オミックスベースの臨床試験市場レポートハイライト

• フェーズIIIセグメントが市場を独占し、2024年の総収益シェアの54.5%を占める。臨床試験統計によると、市場参入企業数が一般的に多い第III相試験の増加が市場成長の原動力となっています。
• 2024年には、オミックス技術から得られた個々の患者プロファイルによるオーダーメイドの介入を促進することで、個別化医療を重視する傾向が強まっていることから、介入研究セグメントが市場を独占しました。
• がんセグメントは、世界のがん罹患率の増加と、より効果的な治療戦略へのニーズの高まりにより、2024年の市場を独占しました。
• 北米のオミックスベースの臨床試験市場が世界の産業を支配し、2024年のシェアは38.0％でした。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 オミックスベースの臨床試験市場の変数、動向、範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/補助的な市場展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 市場分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響分析

第4章 オミックスベースの臨床試験市場：フェーズ、推定・動向分析

• セグメントダッシュボード
• 世界のオミックスベースの臨床試験市場、フェーズ変動分析
• 2018～2030年のフェーズ別のオミックスベースの臨床試験の規模と傾向の世界分析
• フェーズI
• フェーズII
• フェーズIII
• フェーズIV

第5章 オミックスベースの臨床試験市場：試験デザイン、推定・動向分析

• セグメントダッシュボード
• 世界のオミックスベースの臨床試験市場、試験デザイン変動分析
• 2018～2030年の試験デザイン別のオミックスベースの臨床試験の規模と傾向の世界分析
• 介入研究
• 観察研究
• 拡大アクセス研究

第6章 オミックスベースの臨床試験市場：適応症、推定・動向分析

• セグメントダッシュボード
• 世界のオミックスベースの臨床試験市場、適応症変動分析
• 2018～2030年の適応症別のオミックスベースの臨床試験の規模と傾向の世界分析
• 自己免疫/炎症
• 疼痛管理
• がん
• 中枢神経系の状態
• 糖尿病
• 肥満
• 心臓血管
• その他

第7章 オミックスベースの臨床試験市場：地域別、推定・動向分析

• 地域別市場シェア分析、2024年と2030年
• 地域別市場ダッシュボード
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 企業分類
• 企業市況分析、2024年
• 企業プロファイル
  • Parexel International（MA）Corporation
  • Thermo Fisher Scientific Inc.
  • Charles River Laboratories
  • ICON plc
  • SGS Societe Generale de Surveillance SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Laboratory Corporation of America
  • Novo Nordisk A/S
  • Rebus Biosystems, Inc.

List of Tables

• Table 1 List of Secondary Sources
• Table 2 List of Abbreviations
• Table 3 Global Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 4 Global Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 5 Global Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 6 Global Omics-Based Clinical Trials Market, by Region, 2018 - 2030 (USD Million)
• Table 7 North America Omics-Based Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
• Table 8 North America Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 9 North America Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 10 Global Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 11 U.S. Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 12 U.S. Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 13 U.S. Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 14 Canada Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 15 Canada Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 16 Canada Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 17 Mexico Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 18 Mexico Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 19 Mexico Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 20 UK Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 21 UK Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 22 UK Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 23 Germany Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 24 Germany Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 25 Germany Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 26 France Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 27 France Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 28 France Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 29 Italy Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 30 Italy Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 31 Italy Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 32 Spain Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 33 Spain Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 34 Spain Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 35 Sweden Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 36 Sweden Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 37 Sweden Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 38 Norway Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 39 Norway Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 40 Norway Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 41 Denmark Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 42 Denmark Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 43 Denmark Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 44 India Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 45 India Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 46 India Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 47 China Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 48 China Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 49 China Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 50 Japan Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 51 Japan Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 52 Japan Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 53 India Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 54 India Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 55 India Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 56 Australia Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 57 Australia Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 58 Australia Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 59 Thailand Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 60 Thailand Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 61 Thailand Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 62 South Korea Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 63 South Korea Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 64 South Korea Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 65 Brazil Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 66 Brazil Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 67 Brazil Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 68 Argentina Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 69 Argentina Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 70 Argentina Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 71 Saudi Arabia Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 72 Saudi Arabia Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 73 Saudi Arabia Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 74 UAE Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 75 UAE Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 76 UAE Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
• Table 77 Kuwait Omics-Based Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
• Table 78 Kuwait Omics-Based Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
• Table 79 Kuwait Omics-Based Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Information Procurement
• Fig. 2 Primary Research Pattern
• Fig. 3 Market Research Approaches
• Fig. 4 Value Chain-Based Sizing & Forecasting
• Fig. 5 Market Formulation & Validation
• Fig. 6 Omics-Based Clinical Trials Market, Market Segmentation
• Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 9 Porter's Five Forces Analysis
• Fig. 10 PESTEL Analysis
• Fig. 11 Regional Marketplace: Key Takeaways
• Fig. 12 Global Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 13 Global Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 14 Global Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 15 Global Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 16 Global Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 17 Global Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 18 Global Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 19 Global Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 20 Global Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 21 Global Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 22 Global Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 23 Global Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 24 Global Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 25 Global Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 26 Global Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 27 North America Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 28 North America Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 29 North America Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 30 North America Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 31 North America Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 32 North America Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 33 North America Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 34 North America Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 35 North America Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 36 North America Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 37 North America Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 38 North America Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 39 North America Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 40 North America Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 41 North America Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 42 U.S. Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 43 U.S. Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 44 U.S. Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 45 U.S. Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 46 U.S. Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 47 U.S. Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 48 U.S. Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 49 U.S. Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 50 U.S. Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 51 U.S. Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 52 U.S. Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 53 U.S. Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 54 U.S. Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 55 U.S. Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 56 U.S. Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 57 Canada Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 58 Canada Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 59 Canada Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 60 Canada Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 61 Canada Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 62 Canada Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 63 Canada Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 64 Canada Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 65 Canada Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 66 Canada Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 67 Canada Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 68 Canada Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 69 Canada Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 70 Canada Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 71 Canada Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 72 Mexico Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 73 Mexico Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 74 Mexico Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 75 Mexico Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 76 Mexico Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 77 Mexico Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 78 Mexico Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 79 Mexico Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 80 Mexico Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 81 Mexico Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 82 Mexico Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 83 Mexico Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 84 Mexico Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 85 Mexico Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 86 Mexico Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 87 Europe Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 88 Europe Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 89 Europe Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 90 Europe Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 91 Europe Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 92 Europe Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 93 Europe Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 94 Europe Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 95 Europe Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 96 Europe Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 97 Europe Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 98 Europe Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 99 Europe Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 100 Europe Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 101 Europe Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 102 UK Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 103 UK Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 104 UK Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 105 UK Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 106 UK Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 107 UK Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 108 UK Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 109 UK Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 110 UK Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 111 UK Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 112 UK Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 113 UK Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 114 UK Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 115 UK Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 116 UK Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 117 UK Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 118 Germany Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 119 Germany Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 120 Germany Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 121 Germany Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 122 Germany Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 123 Germany Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 124 Germany Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 125 Germany Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 126 Germany Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 127 Germany Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 128 Germany Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 129 Germany Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 130 Germany Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 131 Germany Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 132 France Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 133 France Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 134 France Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 135 France Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 136 France Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 137 France Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 138 France Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 139 France Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 140 France Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 141 France Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 142 France Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 143 France Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 144 France Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 145 France Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 146 France Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 147 Italy Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 148 Italy Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 149 Italy Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 150 Italy Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 151 Italy Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 152 Italy Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 153 Italy Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 154 Italy Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 155 Italy Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 156 Italy Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 157 Italy Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 158 Italy Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 159 Italy Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 160 Italy Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 161 Italy Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 162 Spain Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 163 Spain Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 164 Spain Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 165 Spain Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 166 Spain Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 167 Spain Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 168 Spain Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 169 Spain Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 170 Spain Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 171 Spain Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 172 Spain Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 173 Spain Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 174 Spain Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 175 Spain Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 176 Spain Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 177 Denmark Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 178 Denmark Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 179 Denmark Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 180 Denmark Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 181 Denmark Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 182 Denmark Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 183 Denmark Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 184 Denmark Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 185 Denmark Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 186 Denmark Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 187 Denmark Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 188 Denmark Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 189 Denmark Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 190 Denmark Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 191 Denmark Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 192 Sweden Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 193 Sweden Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 194 Sweden Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 195 Sweden Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 196 Sweden Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 197 Sweden Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 198 Sweden Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 199 Sweden Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 200 Sweden Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 201 Sweden Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 202 Sweden Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 203 Sweden Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 204 Sweden Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 205 Sweden Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 206 Sweden Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 207 Norway Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 208 Norway Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 209 Norway Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 210 Norway Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 211 Norway Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 212 Norway Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 213 Norway Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 214 Norway Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 215 Norway Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 216 Norway Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 217 Norway Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 218 Norway Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 219 Norway Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 220 Norway Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 221 Norway Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 222 Asia Pacific Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 223 Asia Pacific Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 224 Asia Pacific Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 225 Asia Pacific Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 226 Asia Pacific Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 227 Asia Pacific Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 228 Asia Pacific Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 229 Asia Pacific Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 230 Asia Pacific Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 231 Asia Pacific Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 232 Asia Pacific Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 233 Asia Pacific Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 234 Asia Pacific Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 235 Asia Pacific Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 236 Asia Pacific Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 237 China Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 238 China Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 239 China Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 240 China Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 241 China Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 242 China Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 243 China Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 244 China Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 245 China Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 246 China Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 247 China Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 248 China Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 249 China Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 250 China Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 251 China Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 252 Japan Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 253 Japan Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 254 Japan Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 255 Japan Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 256 Japan Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 257 Japan Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 258 Japan Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 259 Japan Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 260 Japan Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 261 Japan Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 262 Japan Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 263 Japan Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 264 Japan Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 265 Japan Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 266 Japan Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 267 India Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 268 India Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 269 India Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 270 India Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 271 India Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 272 India Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 273 India Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 274 India Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 275 India Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 276 India Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 277 India Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 278 India Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 279 India Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 280 India Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 281 India Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 282 Australia Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 283 Australia Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 284 Australia Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 285 Australia Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 286 Australia Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 287 Australia Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 288 Australia Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 289 Australia Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 290 Australia Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 291 Australia Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 292 Australia Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 293 Australia Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 294 Australia Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 295 Australia Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 296 Australia Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 297 Thailand Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 298 Thailand Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 299 Thailand Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 300 Thailand Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 301 Thailand Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 302 Thailand Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 303 Thailand Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 304 Thailand Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 305 Thailand Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 306 Thailand Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 307 Thailand Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 308 Thailand Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 309 Thailand Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 310 Thailand Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 311 Thailand Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 312 South Korea Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 313 South Korea Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 314 South Korea Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 315 South Korea Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 316 South Korea Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 317 South Korea Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 318 South Korea Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 319 South Korea Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 320 South Korea Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 321 South Korea Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 322 South Korea Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 323 South Korea Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 324 South Korea Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 325 South Korea Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 326 South Korea Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)
• Fig. 327 Latin America Omics-Based Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
• Fig. 328 Latin America Omics-Based Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
• Fig. 329 Latin America Omics-Based Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
• Fig. 330 Latin America Omics-Based Clinical Trials Market, For Phase IV, 2018 - 2030 (USD Million)
• Fig. 331 Latin America Omics-Based Clinical Trials Market, For Interventional, 2018 - 2030 (USD Million)
• Fig. 332 Latin America Omics-Based Clinical Trials Market, For Observational, 2018 - 2030 (USD Million)
• Fig. 333 Latin America Omics-Based Clinical Trials Market, For Expanded Access Studies, 2018 - 2030 (USD Million)
• Fig. 334 Latin America Omics-Based Clinical Trials Market, For Oncology, 2018 - 2030 (USD Million)
• Fig. 335 Latin America Omics-Based Clinical Trials Market, For Cardiology, 2018 - 2030 (USD Million)
• Fig. 336 Latin America Omics-Based Clinical Trials Market, For Respiratory Diseases, 2018 - 2030 (USD Million)
• Fig. 337 Latin America Omics-Based Clinical Trials Market, For Skin Diseases, 2018 - 2030 (USD Million)
• Fig. 338 Latin America Omics-Based Clinical Trials Market, For CNS Disorders, 2018 - 2030 (USD Million)
• Fig. 339 Latin America Omics-Based Clinical Trials Market, For Immunology, 2018 - 2030 (USD Million)
• Fig. 340 Latin America Omics-Based Clinical Trials Market, For Genetic Diseases, 2018 - 2030 (USD Million)
• Fig. 341 Latin America Omics-Based Clinical Trials Market, For Others, 2018 - 2030 (USD Million)

Omics-Based Clinical Trials Market Growth & Trends:

The global omics-based clinical trials market size is anticipated to reach USD 51.77 billion by 2030, according to the new report of Grand View Research, Inc. The market is expected to expand at a CAGR of 8.02% from 2025 to 2030. Omics has turned out to be the most advanced approach in molecular research. It includes all the field of biological sciences that ends with the suffix - omics. Various disciplines can be classified as omics such as proteomics, genomics, transcriptomics, and metabolomics. The outbreak of coronavirus accelerated the adoption of new approaches, models, and technology in clinical trials, this has positively impacted market growth.

The outbreak of COVID-19 has caused havoc and has disrupted almost every sector of industry. Initially, the outbreak has negatively impacted the ecosystem of clinical trials and affected many ongoing studies for numerous indications. However, in the second half of 2020, researchers started developing innovative therapeutics and vaccines against COVID-19, which has supported the market recovery and growth, and continuance of business by CROs. There has been an increase in the clinical trials activity with oncology trials attaining historically high levels. The extensive research for understanding the COVID-19 infection has turned the attention to the application of omics-based studies.

For instance, in June 2021, a group of researchers at University Hospital Tuebingen initiated a clinical trial on comparative genetic and immune response analysis of different COVID-19 vaccine candidates using a multi-omics approach. The growing application of spatial OMICS, for the identification of biomarkers, is a major factor boosting the growth of the market. To study the efficacy and toxicity of the drug, spatial OMICS play a major role and have simplified drug discovery and development. Biomarker identification along with the clinical application is widely used in drug development and discovery. Biomarkers are used to identify the pathway of the diseases and the progression and help to understand the cause.

The rising prevalence of chronic diseases such as cancer and cardiac disorders and the increasing demand for omics-based clinical trials in developing countries are boosting the market's growth. Cancer is one of the leading causes of death in the United States. In 2018 alone, there were an estimated 1,735,350 new diagnoses and 609,640 cancer-related deaths. Single-cell multi-OMIC analysis is a novel tool that is opening doors in cancer drug development and further advance the current treatment options. The market is also driven by a rising number of biologics, demand for advanced technologies, and the need for personalized medicines and orphan drugs. Additionally, growing biotechnology and the pharmaceutical industry have propelled the demand for non-invasive instruments, full applications for single-cell multi-omics technology, and conventional labs are bolstering future market growth.

Omics-Based Clinical Trials Market Report Highlights:

• The phase III segment dominated the market, accounting for 54.5% of the total revenue share in 2024. Clinical trial statistics indicate that market growth is driven by an increase in phase III trials, which typically involve a large number of participants.
• The interventional studies segment dominated the market in 2024 owing to its growing emphasis on personalized medicine by facilitating tailored interventions based on individual patient profiles derived from omics technologies.
• The oncology segment dominated the market in 2024 owing to increasing prevalence of cancer globally coupled with growing need for more effective treatment strategies.
• North America omics-based clinical trials market dominated the global industry and accounted for a 38.0% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis
  • 1.6.2. Bottom-up Approach
• 1.7. List of Secondary Sources
• 1.8. List of Abbreviations
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Omics-Based Clinical Trials Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Investment by Major Pharmaceutical Companies
    • 3.2.1.2. Shift Towards Personalized Medicine
    • 3.2.1.3. Growing Prevalence of Chronic Disorders
    • 3.2.1.4. Increasing Partnership and Collaboration
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Rising Costs of Clinical Trials
• 3.3. Market Analysis Tools
  • 3.3.1. Porter's Five Forces Analysis
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Omics-Based Clinical Trials Market: Phase Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Omics-Based Clinical Trials Market; Phase Movement Analysis
• 4.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Phase, 2018 to 2030 (USD Million)
• 4.4. Phase I
  • 4.4.1. Phase I market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Phase II
  • 4.5.1. Phase II market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Phase III
  • 4.6.1. Phase III market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Phase IV
  • 4.7.1. Phase IV market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Omics-Based Clinical Trials Market: Study Design Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Omics-Based Clinical Trials Market; Study Design Movement Analysis
• 5.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Study Design, 2018 to 2030 (USD Million)
• 5.4. Interventional Studies
  • 5.4.1. Interventional studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Observational Studies
  • 5.5.1. Observational studies market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Expanded Access Studies
  • 5.6.1. Expanded access studies market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Omics-Based Clinical Trials Market: Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Omics-Based Clinical Trials Market; Indication Movement Analysis
• 6.3. Global Omics-Based Clinical Trials Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 6.4. Autoimmune/inflammation
  • 6.4.1. Autoimmune/inflammation market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Pain management
  • 6.5.1. Pain management market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Oncology
  • 6.6.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. CNS conditions
  • 6.7.1. CNS conditions market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Diabetes
  • 6.8.1. Diabetes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. Obesity
  • 6.9.1. Obesity market estimates and forecasts 2018 to 2030 (USD Million)
• 6.10. Cardiovascular
  • 6.10.1. Cardiovascular market estimates and forecasts 2018 to 2030 (USD Million)
• 6.11. Others
  • 6.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Omics-Based Clinical Trials Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Company Market Position Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. Parexel International (MA) Corporation
    • 8.3.1.1. Company overview
    • 8.3.1.2. Financial performance
    • 8.3.1.3. Service benchmarking
    • 8.3.1.4. Strategic initiatives
  • 8.3.2. Thermo Fisher Scientific Inc.
    • 8.3.2.1. Company overview
    • 8.3.2.2. Financial performance
    • 8.3.2.3. Service benchmarking
    • 8.3.2.4. Strategic initiatives
  • 8.3.3. Charles River Laboratories
    • 8.3.3.1. Company overview
    • 8.3.3.2. Financial performance
    • 8.3.3.3. Service benchmarking
    • 8.3.3.4. Strategic initiatives
  • 8.3.4. ICON plc
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Service benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. SGS Societe Generale de Surveillance SA
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Service benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Eli Lilly and Company
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Service benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Pfizer Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Service benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Laboratory Corporation of America
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Service benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Novo Nordisk A/S
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Service benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Rebus Biosystems, Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Service benchmarking
    • 8.3.10.4. Strategic initiatives